NEWS |
Clarification
In a Jan. 5, 2000, News article (p.6) on STI-571, a new drug that selectively targets chronic myelogenous leukemia cells, it was stated that Herceptin® (trastuzumab) was the first monoclonal antibody to be approved by the Food and Drug Administration for cancer treatment. However, the first was actually Rituxan® (rituximab), which was approved and marketed in November 1997 for the treatment of non-Hodgkins B-cell lymphoma.
This article has been cited by other articles in HighWire Press-hosted journals:
-
van der Zee, J.
(2002). Heating the patient: a promising approach?. Ann Oncol
13: 1173-1184
[Abstract]
[Full Text]